Vázquez-Martínez JL, Coreño-Juárez MO, Montaño-Estrada LF, Attlan M, Gómez-Dantés H

Language: English
References: 28
Page: 165-170
PDF size: 58.58 Kb.

ABSTRACT

Objective. To determine the seroprevalence of hepatitis B in pregnant women from several regions of Mexico, as well as the risk factors associated with its occurrence. Material and Methods. A cross-sectional study was conducted between May and August 2000. It included 9 992 pregnant women attending the health services of the Mexican Institute of Social Security (Instituto Mexicano del Seguro Social-IMSS) in five cities: Tijuana, Ciudad Juarez, Acapulco, Cancun, and Mexico City (Northeast and Southeast regions). Results. The overall prevalence for confirmed cases was 1.65% (165/ 9 992). The prevalences for individual cities were as follows: Tijuana, 1.27%; Ciudad Juarez, 1.46%; Acapulco, 2.47%; Cancun, 0.93%; Northeastern Mexico City, 1.20%, and Southeastern Mexico City, 2.52%. The risk factors found to be associated with HBsAg were: age, age at first sexual intercourse, city (Acapulco and Southeastern Mexico City), and marital status (single or divorced). Conclusions. The prevalence of HBsAg in pregnant women (1.65%) was greater than that reported in previous studies and showed geographical differences. This high prevalence suggests that a considerable amount of cases of hepatitis B occurs perinatally and through contact with carriers in the general population. Vaccination of newborns of high-risk pregnant women should be considered.

REFERENCES

1. World Health Organization. Hepatitis B vaccine: Making global progress. Epi Update 31. 1996. Ginebra: WHO, 1996.

2. Lee WM. Hepatitis B Virus Infection. N Engl J Med 1997;337:1733-1745.

3. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22707 men in Taiwan. Lancet 1981;2:1129-1133.

4. Thêmis RS, Fonseca JC, Rivera L, Fay OH, Tapia R, Santos JI et al. Hepatitis B seroprevalence in Latin America. Rev Panam Salud Publica 99;6(6): 378-383.

5. Soares MCP, Menezes RC, Martins SJ, Bensabath G. Epidemiologia dos vírus das hepatites B, C, e D na tribu indígena Parakana Amazônia Oriental Brasileira. Bol Oficina Sanit Panam 1994;117:124-134.

6. Lok AS, Heathcote JE, Hoofnagle JH. Management of Hepatitis B: 2000. Gastroenterology 2001;120:1828-1853.

7. McQuillan G, Coleman PJ, Kruszon-Moran D, Moyer LA, Moyer LA, Lambert SB et al. Prevalence of Hepatitis B Virus Infection in the United States: The National Health and Nutrition Examination Surveys, 1976 Through 1994. Am J Public Health 1999;89:14-18.

8. Sáenz-González MC. Hepatitis B, Hepatitis C, Hepatitis D y hepatitis G, Enfermedades Transmisibles-Hepatitis B: Medicina Preventiva y Salud Pública. Barcelona, España: Ed. Mason, 2001:540-548.

9. Halsey NA. Discussion of Immunization Practices Advisory Committee/American Academy of Pediatrics. Recommendations for universal infant hepatitis B vaccination. Pediatr Infect Dis J 1993 May;12(5):446-449.

10. Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination in national immunization programmes. BMJ 1997;314:1033-1036.

11. World Health Organization. Expanded Programme on Immunization Global Advisory Group. Weekly Epidemiol Record 1992;3:11-16.

12. Centers For Disease Control. Hepatitis B Virus. A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR 1991;40(RR-13):1-25.

13. Centers For Disease Control. Maternal hepatitis B screening practices — California, Connecticut, Kansas, and United States, 1992-1993. MMWR Morb Mortal Wkly Rep 1994;43:311- 320.

14. Mortimer PP, Miller E. Commentary: Antenatal screening and targeting should be sufficient in some countries. BMJ 1997;314:1036-1037.

15. Alvarez-Muñoz MT, Vázquez-Rosales JG, Torres-López J, Arredondo-García JL, Bustamante-Calvillo ME, Del Rey-Pineda G et al. Infection of pregnant women with hepatitis B and C viruses and risk for vertical transmission. Arch Med Res 1997;28(3):415-419.

16. Ortiz-Ibarra FJ, Figueroa-Damián R, Lara-Sánchez J, Arredondo-García JL, Ahued-Ahued JR. Seroprevalence of hepatitis A, B, C and D infection in pregnant women. Salud Publica Mex 1996; 38:317-322.

17. Hadler SC, Fay OH, Pinheiro F, Maynard JE. La hepatitis en las Américas. Informe del Grupo Colaborador de la OPS. Bol Oficina Sanit Panam 1987;103(3):185-209.

18. Organización Panamericana de la Salud. Medicina transfusional en América Latina 1994-2000. Washington, DC: OPS, 2001;OPS/HSE-LAB/04.2001.

19. Méndez-Sanchez N, Baptista-González H, Sánchez-Gómez RH, Bordes-Aznar J, Uribe-Esquivel M. Prevalence of type C and B hepatitis in blood donors at a third level hospital of Mexico City. Salud Publica Mex 1999;41:475-478.

20. Souto-Meiriño CA, Simón-Domínguez J, Pulido-Priego MA, Hernández-Pérez A, García-Hernández IC, Del Río-Chiriboga CA. Prevalence of A, B and C hepatitis markers in a Mexico City hospital. Salud Publica Mex 1994; 36:257-262.

21. Landa L. Seroepidemiología de la hepatitis B. Gac Med Mex 1976;111(2):108-113.

22. Al-Shamahy H. Prevalence of hepatitis B surface antigen and risk factors of HVB infection in a sample of healthy mothers and their infants in Sana,A, Yemen. Ann Saudi Med 2000;20(5):464-467.

23. Instituto Mexicano del Seguro Social. Boletín Epidemiológico Anual 1999, México, DF: IMSS, 1999.

24. World Health Organization. WHO-recommended standards for surveillance of selected vaccine-preventable diseases. Ginebra: WHO, 1998.

25. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo ME. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341:122-126.

26. Suslov AP, Kuzin SN, Sadikova NV, Elgort DA, Feldsherova AA, Nikolaev VL et al. Performance of ELISA HBsAg test kits with use of the different types of panels containing HBsAg. Russian J Immunol

27. 2000;5(2):218-226.

28. Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: A global perspective. Vaccine 1999;17: 1730-1733.